TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10959813
Drug: Interferon combined
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon combined with ribavirin (1000-1200 mg/day) for 24 weeks
Study: 1654194
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) treatment with 370 mg of monoclonal antibody 494/32 (100 mg loading dose, 9 x 30 mg continuing within 10 days)
Study: 1654194
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional anti-cancer treatment (Control)
Study: 6352612
Drug: Ceftazidime and
Normalized name: Ceftazidime and Avibactam for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime and tobramycin combination
Study: 26089136
Drug: Controlled-Release Sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-Release Sarpogrelate 300 mg once daily
Study: 26089136
Drug: Immediate-Release Sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-Release Sarpogrelate 100 mg three times daily
Study: 26089136
Drug: Controlled-Release Sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-Release Sarpogrelate
Study: 26089136
Drug: Immediate-Release Sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-Release Sarpogrelate
Study: 21629370
Drug: Daily functioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily functioning
Study: 21629370
Drug: Hypnotic consumption
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic consumption
Study: 19083075
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg of vitamin D3 daily
Study: 19083075
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg of vitamin D3 daily
Study: 19083075
Drug: 75 microg
Normalized name: Norgestrel 75 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg of vitamin D3 daily
Study: 19083075
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg of vitamin D3 daily
Study: 19083075
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of vitamin D3 daily
Study: 19083075
Drug: S-calcium (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-calcium (not specified dosage)
Study: 16784967
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg before each meal (300 mg/d) for 3 months
Study: 16344404
Drug: ISDN/HYD therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN/HYD therapy
Study: 10596659
Drug: 2,200 mg
Normalized name: omega 3/dha/epa/other om3/D3 2,200 mg (1,570 mg-610 mg-20 mg)-1,000 unit/5 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,200 mg amoxicillin‐clavulanic acid
Study: 10596659
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg cefuroxime
Study: 8691923
Drug: r-hGH treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH treatment (subcutaneous dose ranged between 12.2 and 21.0 U/m2 per week for the first 2 years, then 20 U/m2 per week thereafter)
Study: 8691923
Drug: Observation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation group (7 short children who declined treatment)
Study: 29044718
Drug: Child‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child‐ and Family‐Focused Cognitive Behavioral Therapy (CFF‐CBT)
Study: 29044718
Drug: Psychotherapy treatment‐as‐usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment‐as‐usual (TAU)
Study: 26883141
Drug: TC-based CCRT
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC-based CCRT (carboplatin AUC: 2, paclitaxel 35mg/m²) followed by TC-based consolidation chemotherapy (carboplatin AUC: 5, paclitaxel 175mg/m²)
Study: 25402544
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) twice daily (bid)
Study: 18507956
Drug: Traditional medications
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medications
Study: 11840081
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose Hib polysaccharide-tetanus toxoid conjugate vaccine
Study: 11840081
Drug: 1/10 dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10 dilution of Hib polysaccharide-tetanus toxoid conjugate vaccine
Study: 10354656
Drug: Lithium (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (1,200 mg)
Study: 8577796
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (70 mg)
Study: 8577796
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (250 mg)
Study: 1959958
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days
Study: 1959958
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days (if started by 16-19 weeks of gestation)
Study: 31675919
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (600,000 IU of 25(OH)D in a single oral administration)
Study: 29246284
Drug: ALA-DAG (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-DAG (2.5 g/day)
Study: 29246284
Drug: ALA-TAG (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-TAG (2.5 g/day)
Study: 26672246
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine comprehensive treatment only)
Study: 21471262
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion starting after induction of anesthesia with an initial bolus of 12 μg·kg(‐1) for 10 min, followed by 0.1 μg·kg(‐1)·min(‐1) for 24 h
Study: 15121557
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600 microg misoprostol
Study: 15121557
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of 600 microg misoprostol
Study: 11477729
Drug: Aerosolized INS
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized INS 365 (20, 40, 80, and 100 mg)
Study: 11477729
Drug: Aerosolized INS
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized INS 365 (80 mg and 100 mg)
Study: 25312436
Drug: Perindopril-indapamide (4/1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril-indapamide (4/1.25 mg)
Study: 14516415
Drug: Ketorolac (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10 mg, p.o.)
Study: 8859174
Drug: Regional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional infusion chemotherapy with FUDR
Study: 2983461
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir 200 mg X 4 daily for 28 days
Study: 2983461
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir (after interruption of placebo)
Study: 2983461
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir and placebo
Study: 31664468
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 100-150 mg/kg/min
Study: 29521134
Drug: Tylerdipine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tylerdipine hydrochloride (5, 15, 20, 25, and 30 mg)
Study: 26574928
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with fixed appliance for 6 months
Study: 26574928
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group awaiting treatment
Study: 25183688
Drug: Probiotic L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic L. plantarum IS-10506 (10(10)CFU/day)
Study: 25183688
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of probiotic L. plantarum IS-10506 (10(10)CFU/day) and zinc (8mg elemental zinc)
Study: 20482515
Drug: Oral naltrexone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone, 50 mg
Study: 20482515
Drug: Intramuscular naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naltrexone (active for one month)
Study: 20482515
Drug: Oral naltrexone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone, higher doses
Study: 15228129
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5%/clindamycin 1% topical gel (BP/C)
Study: 12568205
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg for 8 weeks
Study: 12568205
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily after washout
Study: 9525448
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (200 microg fluticasone propionate twice daily; n = 16)
Study: 9525448
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo nasal spray (n = 17)
Study: 8580622
Drug: IgA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibodies to BSA
Study: 8580622
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to BSA
Study: 8580622
Drug: IgA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibodies to ovalbumin
Study: 8580622
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to ovalbumin
Study: 8580622
Drug: IgA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibodies to beta-lactoglobulin
Study: 8580622
Drug: IgA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibodies to cow's milk
Study: 30168004
Drug: Evocalcet 1-20
Normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Evocalcet 1-20 mg (single dose)
Study: 30168004
Drug: Evocalcet 6
Normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Evocalcet 6 and 12 mg (multiple doses)
Study: 30168004
Drug: Evocalcet up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet up to 12 mg (multiple doses)
Study: 30168004
Drug: Evocalcet up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet up to 20 mg (single dose)
Study: 24560135
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 267 mg daily
Study: 20636275
Drug: SQV/ritonavir (SQV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV/ritonavir (SQV/r) 1000 mg/ritonavir 100 mg BID
Study: 20636275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (habitual treatment)
Study: 7595738
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (IFN‐alpha 2a) 20 x 10(6) U/m2 administered three times each week for 12 weeks
Study: 2147842
Drug: Enoximone (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (total dose of 1.5 mg/kg)
Study: 2147842
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (Enoximone, Dobutamine, Sodium nitroprussiate)
Study: 31027300
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber cereal (90 g, 11 g fiber/90 g) consumed at Sohor for 20 consecutive days
Study: 31027300
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber cereal (90 g, 11 g fiber/90 g)
Study: 27809609
Drug: Control Device:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Device: FDA‐cleared syringe driver with FDA‐cleared infusion set
Study: 15776301
Drug: alpha‐GST concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐GST concentrations (> 490 microg L(‐1))
Study: 12081988
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with adjustment for postrandomization statin use
Study: 7840322
Drug: Younger reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger reference subjects (< 33 years old) taking no supplement
Study: 17892996
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of mononuclear bone marrow cells (mBMCs)
Study: 16841333
Drug: alpha‐tocopherol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol (400 IU/day) and beta‐carotene (30 mg/day) supplements
Study: 12968238
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous administration of low‐dose fenoldopam (0.1‐0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B)
Study: 1623694
Drug: Niguldipine (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niguldipine (0.3, 0.6, and 0.9 mg intravenously; 8 and 16 mg orally)
Study: 1623694
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 mg intravenously; 20 mg orally)
Study: 6378555
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received preoperative systemic antibiotic prophylaxis
Study: 29303212
Drug: Topical methylprednisolone
Normalized name: methylprednisolone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methylprednisolone cream
Study: 25884010
Drug: NP001 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP001 2 mg/kg
Study: 25884010
Drug: NP001 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP001 1 mg/kg
Study: 15080830
Drug: Sublingual swallow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual swallow immunotherapy (SLIT)
Study: 9429007
Drug: Homoeopathic medicine
Normalized name: Homoeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic medicine
Study: 3435119
Drug: Cefpimizole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpimizole (100 mg to 2000 mg)
Study: 3435119
Drug: Cefpimizole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpimizole (500 mg and 1000 mg twice-daily)
Study: 27075708
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family systems therapy‐diabetes (BFST‐D) via telehealth
Study: 27075708
Drug: Traditional (Clinic)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional (Clinic) treatment
Study: 24369254
Drug: INFα‐2b monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: INFα‐2b monotherapy (5×10(6), three times a week)
Study: 24369254
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with entecavir (0.5 mg/day) plus adefovir (10 mg/day)
Study: 16791523
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug Free Years program (PDFY)
Study: 10920066
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 300 mg/d
Study: 10920066
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 600 mg/d
Study: 10920066
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 1200 mg/d
Study: 6531951
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of trivalent influenza subunit vaccine (7 micrograms per dose)
Study: 27241710
Drug: Levodopa 100
Normalized name: levodopa 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg/carbidopa 25 mg
Study: 18544002
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg intravenously every 12 hours for 48 hours
Study: 18544002
Drug: Dipyrone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 2.5 g intravenously intraoperatively, followed by 1 g every 6 hours for 48 hours
Study: 18544002
Drug: Cumulative piritramide
Normalized name: piritramide
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative piritramide administration
Study: 11528495
Drug: Fruit juice
Normalized name: Fruit Juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit juice (1 l per day)
Study: 11528495
Drug: Fruit-vegetable-concentrate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit-vegetable-concentrate (30 ml per day)
Study: 9371896
Drug: Zolmitriptan doses
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan doses > or = 2.5 mg
Study: 9371896
Drug: Zolmitriptan (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (second dose)
Study: 9371896
Drug: Zolmitriptan doses
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan doses < or = 2.5 mg
Study: 1553930
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4.2 g of omega-3 fatty acids per day)
Study: 25242558
Drug: Ixekizumab 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 120 mg subcutaneous every 4 weeks during OLE
Study: 20075184
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (500 mg, intravenous)
Study: 20075184
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 mg, intramuscular)
Study: 12593521
Drug: BDP via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP via metered-dose inhaler (MDI) 1,600 microg
Study: 12593521
Drug: BDP suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP suspension for nebulization 1,600 microg
Study: 12593521
Drug: BDP suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP suspension for nebulization 3,200 microg
Study: 12165579
Drug: Single remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single remote course of antenatal corticosteroids (two 12‐mg doses of betamethasone)
Study: 12165579
Drug: Weekly courses
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly courses of antenatal corticosteroids
Study: 7789043
Drug: Clonidine (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (infusion rates of 16-2048 ng/min)
Study: 6107587
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral disopyramide
Study: 6652010
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg into the extradural space
Study: 29774465
Drug: 4000 mg
Normalized name: talc 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 mg myo-inositol plus 400 mcg folic acid (MI treatment)
Study: 29774465
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg D-chiro-inositol plus 400 mcg folic acid (DCI treatment)
Study: 29774465
Drug: 1100/27.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100/27.6 mg myo/D-chiro-inositol plus 400 mcg folic acid (MI plus DCI treatment)
Study: 29774465
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg folic acid (control treatment)
Study: 27760402
Drug: CC-60 (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-60 (21 mg/day carotenes)
Study: 27760402
Drug: TRF-80 (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRF-80 (420 mg/day tocotrienol + 132 mg/day tocopherol)
Study: 24923573
Drug: Thumbtack intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thumbtack intradermal (TI) needles (control)
Study: 22836707
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (50 min daily training for 6 months)
Study: 8789545
Drug: Cetirizine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (30 mg daily for 5 days)
Study: 8789545
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg daily for 5 days)
Study: 1615546
Drug: Intravenous glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycerol (500 ml of 10% glycerol in saline by intravenous infusion over 4 hours on 6 consecutive days)
Study: 1615546
Drug: Saline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline treatment (placebo)